Observational studyCancer medicine2025

Final Analysis of Post-Marketing Surveillance for Avelumab + Axitinib in Patients With Renal Cell Carcinoma in Japan.

Norio Nonomura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.